nasdaq:elox
|
18504171
|
Apr 21st, 2024 12:00AM
|
Eloxx Pharmaceuticals
|
2.8K
|
13.00
|
Open
|
|
Apr 20th, 2024 11:23PM
|
Apr 20th, 2024 11:23PM
|
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
|
Open
|
Biotech, Rare Diseases, Pharmaceuticals, Drug Development, Life Sciences, and Healthcare
|
Open
|
480 Arsenal Way Suite 130
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
Eloxx Pharmaceuticals
|
|
|
nasdaq:elox
|
18504171
|
Apr 20th, 2024 12:00AM
|
Eloxx Pharmaceuticals
|
2.8K
|
13.00
|
Open
|
|
Apr 19th, 2024 11:20PM
|
Apr 20th, 2024 04:56PM
|
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
|
Open
|
Biotech, Rare Diseases, Pharmaceuticals, Drug Development, Life Sciences, and Healthcare
|
Open
|
480 Arsenal Way Suite 130
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
Eloxx Pharmaceuticals
|
|
|
nasdaq:elox
|
18504171
|
Apr 19th, 2024 12:00AM
|
Eloxx Pharmaceuticals
|
2.8K
|
13.00
|
Open
|
|
Apr 18th, 2024 11:27PM
|
Apr 18th, 2024 11:27PM
|
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
|
Open
|
Biotech, Rare Diseases, Pharmaceuticals, Drug Development, Life Sciences, and Healthcare
|
Open
|
480 Arsenal Way Suite 130
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
Eloxx Pharmaceuticals
|
|
|
nasdaq:elox
|
18504171
|
Apr 18th, 2024 12:00AM
|
Eloxx Pharmaceuticals
|
2.8K
|
13.00
|
Open
|
|
Apr 17th, 2024 11:35PM
|
Apr 18th, 2024 06:16PM
|
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
|
Open
|
Biotech, Rare Diseases, Pharmaceuticals, Drug Development, Life Sciences, and Healthcare
|
Open
|
480 Arsenal Way Suite 130
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
Eloxx Pharmaceuticals
|
|
|
nasdaq:elox
|
18504171
|
Apr 17th, 2024 12:00AM
|
Eloxx Pharmaceuticals
|
2.8K
|
13.00
|
Open
|
|
Apr 16th, 2024 11:18PM
|
Apr 17th, 2024 02:40PM
|
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
|
Open
|
Biotech, Rare Diseases, Pharmaceuticals, Drug Development, Life Sciences, and Healthcare
|
Open
|
480 Arsenal Way Suite 130
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
Eloxx Pharmaceuticals
|
|
|
nasdaq:elox
|
18504171
|
Apr 16th, 2024 12:00AM
|
Eloxx Pharmaceuticals
|
2.8K
|
13.00
|
Open
|
|
Apr 15th, 2024 11:14PM
|
Apr 16th, 2024 10:57AM
|
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
|
Open
|
Biotech, Rare Diseases, Pharmaceuticals, Drug Development, Life Sciences, and Healthcare
|
Open
|
480 Arsenal Way Suite 130
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
Eloxx Pharmaceuticals
|
|
|
nasdaq:elox
|
18504171
|
Apr 15th, 2024 12:00AM
|
Eloxx Pharmaceuticals
|
2.8K
|
13.00
|
Open
|
|
Apr 14th, 2024 11:09PM
|
Apr 15th, 2024 04:38PM
|
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
|
Open
|
Biotech, Rare Diseases, Pharmaceuticals, Drug Development, Life Sciences, and Healthcare
|
Open
|
480 Arsenal Way Suite 130
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
Eloxx Pharmaceuticals
|
|
|
nasdaq:elox
|
18504171
|
Apr 14th, 2024 12:00AM
|
Eloxx Pharmaceuticals
|
2.8K
|
13.00
|
Open
|
|
Apr 13th, 2024 10:58PM
|
Apr 14th, 2024 10:57AM
|
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
|
Open
|
Biotech, Rare Diseases, Pharmaceuticals, Drug Development, Life Sciences, and Healthcare
|
Open
|
480 Arsenal Way Suite 130
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
Eloxx Pharmaceuticals
|
|
|
nasdaq:elox
|
18504171
|
Apr 13th, 2024 12:00AM
|
Eloxx Pharmaceuticals
|
2.8K
|
13.00
|
Open
|
|
Apr 12th, 2024 10:49PM
|
Apr 13th, 2024 11:24AM
|
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
|
Open
|
Biotech, Rare Diseases, Pharmaceuticals, Drug Development, Life Sciences, and Healthcare
|
Open
|
480 Arsenal Way Suite 130
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
Eloxx Pharmaceuticals
|
|
|
nasdaq:elox
|
18504171
|
Apr 12th, 2024 12:00AM
|
Eloxx Pharmaceuticals
|
2.8K
|
13.00
|
Open
|
|
Apr 11th, 2024 10:54PM
|
Apr 12th, 2024 08:19AM
|
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
|
Open
|
Biotech, Rare Diseases, Pharmaceuticals, Drug Development, Life Sciences, and Healthcare
|
Open
|
480 Arsenal Way Suite 130
|
Watertown
|
Massachusetts
|
US
|
02472
|
|
Eloxx Pharmaceuticals
|
|
|